Close
FINDING CURES TOGETHER<sup>SM</sup>

Pancreatic Cancer Action Network-AACR Career Development Awards

 

The Pancreatic Cancer Action Network-AACR Career Development Awards support junior faculty who are in the first four years of a faculty appointment (at the start of the grant term) to conduct pancreatic cancer research and establish successful career paths in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.

 

2014 Grantees

David G. DeNardo, PhDDavid G. DeNardo, PhD
Assistant Professor, Department of Medicine and Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO

Origins and Impact of Macrophages in Pancreatic Cancer 

Pancreatic cancer carries a dismal prognosis. The success of current treatments is measured by response rates instead of cures. A promising way to improve outcomes for patients is to target the tissue and cellular environment within which the tumor exists. Tumor-associated macrophages (TAMs) reside within the environment of pancreatic tumors and the presence of high numbers of these macrophages correlates with poor clinical outcomes in patients with pancreatic cancer. Thus, TAMs have become important targets for drugs in recent clinical trials. The classical assumption has been that TAMs are recruited from cells in the blood, which are continuously generated in the bone marrow. This assumption has been the basis for several clinical trials targeting macrophage recruitment. However, using several novel techniques to track these immune cells, we found that pancreatic tumors are often heavily infiltrated with macrophages derived from cell division rather than recruitment from the blood. These resident proliferating macrophages are prominent in human pancreatic cancer and can predict poor patient outcomes. However, the mechanisms by which this macrophage subset might impact tumor progression or response to current clinical treatments have not been examined. We hypothesize that resident proliferating macrophages are critical early mediators of tumor inflammation and drivers of tumor metastasis. We will test this hypothesis using a combination of 1) mouse models of pancreatic cancer in combination with unique cellular tracing to follow macrophages and 2) assessment of proliferating macrophages in human PC tissue samples to determine their impact on patient outcomes.

Top of Page

Pancreatic Cancer Action Network – AACR Career Development Award, in memory of Skip Viragh

Eugene J. Koay, MD, PhD Eugene J. Koay, MD, PhD
Assistant Professor, University of Texas M.D. Anderson Cancer Center, Houston, TX

Changes in Mass Transport as a Biomarker of Response in Pancreatic Cancer 

There has been significant progress in the understanding of the biology of pancreatic cancer. As novel strategies emerge from these scientific discoveries and are tested in phase I/II clinical trials, it will be increasingly important to have an early biomarker of response to therapy so that promising strategies can reach patients quickly. Currently, such a biomarker has not been identified for pancreatic tumors.

Dr. Koay’s pilot studies have revealed a promising candidate for this purpose. He worked with a multi-disciplinary team to develop a method to quantify enhancement properties of pancreatic tumors from diagnostic computed tomography (CT) scans and correlated these properties with patient outcome. In two trials of chemoradiation for unresectable pancreatic cancer, patients who had a measureable decrease in enhancement of their pancreatic tumors after chemoradiation treatment showed significantly better tumor control (86% with tumor control at 2 years) compared to patients whose tumors exhibited stable or increased enhancement after treatment (34% with tumor control at 2 years), independent of therapy regimen, change in tumor size, and receipt of curative-intent surgery.

This PANCAN proposal involves a multi-institutional collaboration to test the idea that tumor control is associated with changes in tumor enhancement. In collaboration with investigators at Johns Hopkins, the measurements of enhancement from CT scans before and after treatment will be compared with tumor control for large datasets of patients with pancreatic cancer who received chemotherapy and radiation. Simultaneously, a prospective registry trial at MD Anderson will test the same idea for patients who receive chemotherapy alone for unresectable, non-metastatic pancreatic cancer. To understand the underlying biology of the observation, the researchers will analyze pancreatic tumors that were treated with chemoradiation prior to surgery, correlating the CT enhancement profiles with specific markers of therapy resistance in the specimens.

In summary, Dr. Koay and his team will perform a large-scale validation plan to establish a clinically useful and scientifically meaningful method to help accelerate promising new treatment strategies for pancreatic cancer and more rapidly improve patient outcomes.

Top of Page

Florencia McAllister, MDFlorencia McAllister, MD
Assistant Professor, University of Texas M.D. Anderson Cancer Center, Houston, TX

Targeting IL-17 signaling Axis in Pancreatic Ductal Adenocarcinoma 

Even though a Kras mutation is enough to initiate early pre-malignant lesions, the mechanisms required for the progression to pancreatic cancer are unknown. It is well known that inflammation is a risk factor for cancer and it has been well established that pancreatic chronic inflammation can accelerate the development of pancreatic cancer. Dr McAllister has recently found that activation of KrasG12D in murine adult acinar cells induces expression of functional IL-17 receptors (IL-17RA) on emerging PanIN epithelial cells, accompanied by pancreatic infiltration by IL-17-producing CD4+ and gd-T cells. Furthermore, she has shown that IL-17-producing T cells are early drivers of pancreatic neoplasia and mediate much of the increase in PanIN formation observed in chronic pancreatitis. She is now going to extend these studies to determine the role of IL-17 signaling in advanced disease, including the preclinical evaluation of clinical-grade neutralizing antibodies targeting IL-17 signaling in established murine pancreatic cancer. Furthermore, she is planning to dissect the specific compartment required for the pro-tumorigenic IL-17 signaling in pancreatic tumor development. Finally, she will also investigate how systemic TH17 immune responses, including changes in the gut microbiome, can affect pancreatic tumorigenesis.

In sum, she considers that better understanding of the pancreatic hematopoietic-to-epithelial pro-tumorigenic IL-17 signaling axis can result in more effective strategies for the prevention and treatment of pancreatic cancer.  

Top of Page

Kenneth L. Scott, PhDKenneth L. Scott, PhD
Assistant Professor, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX

Functionalizing Metabolic Pathway Driver Aberrations in Pancreatic Cancer 

Dr. Scott’s proposal focuses on identifying genes that promote pancreatic ductal adenocarcinoma (PDAC) development and progression (referred to here as PDAC “driver” genes). Identifying PDAC drivers and understanding their mechanism-of-action is critically important, as this information could inform new PDAC diagnostics and therapeutics. To identify such drivers, Dr. Scott’s laboratory developed a novel genetic screening platform that integrates (1) their collection of over 32,000 human genes, (2) an innovative strategy that enables rapid modeling of barcoded mutant genes based on large-scale PDAC genome sequencing efforts and (3) a unique human cell system that allows simultaneous expression of genes found mutated in PDAC to identify those that cooperate with KRAS, the major driver gene found in pancreatic cancer, to promote PDAC tumor development and metastasis in mice. Dr. Scott’s team used these tools to identify novel PDAC driver genes, one of which (NADK) is known to influence metabolic pathways that regulate cell growth and resistance to growth-related cell stress.  Recent work by others demonstrated the importance of metabolic pathways in promoting and maintaining PDAC tumor growth, thus Dr. Scott hypothesizes that inactivating the NADK protein or inhibiting NADK’s activated pathways will provide new ways to treat pancreatic cancer patients. Dr. Scott will test this notion using a series of genetic experiments employing a panel of PDAC cell models and metabolic assays to better understand the mechanisms-of-action for both normal and mutated (found in patients) NADK. Dr. Scott’s team will also assess NADK as a new drug target by examining tumor growth and signaling through metabolic pathways following inhibiting NADK expression by genetic means or inhibiting NADK activity by use of pharmacological agents. Finally, Dr. Scott’s team will mine large-scale genomics data collected from PDAC tumors to create collections of other mutated genes with high probability of impacting metabolic pathways.  These genes will be entered into innovative screens similar to those that identified NADK to identify new metabolic drivers, which with his combined studies on NADK, will illuminate gene pathways promoting PDAC progression with the goal of identifying new drug targets and/or detection biomarkers critically needed for pancreatic cancer patients who currently have few effective treatment options.

Top of Page

Kathryn E. Wellen, PhDKathryn E. Wellen, PhD
Assistant Professor, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA

Understanding Metabolic Control of the Pancreatic Cancer Epigenome

Novel strategies are desperately needed for the treatment of pancreatic ductal adenocarcinoma, a disease with a dismal prognosis and an average survival of 6 months after diagnosis.  Deregulation of cellular epigenetics (reversible chemical modifications to DNA and DNA-associated proteins) is essential for normal cells to transform into cancer cells. The mechanisms that cause epigenetic alterations in cancer cells are poorly understood, however, and insight into these mechanisms would facilitate the design of more specific therapeutics.  Recently, evidence has emerged showing that epigenetic modifications are regulated by cellular metabolites (substances produced by nutrient breakdown in the cell).  Mutations in Kras, a cancer-gene that is almost universally mutated in pancreatic ductal adenocarcinoma, have been shown to orchestrate extensive rewiring of nutrient metabolism.  This research plan will address the hypothesis that mutant Kras causes cells to shift the balance of cellular metabolites, resulting in an altered epigenetic state that facilitates tumor cell growth. This hypothesis is based on findings that changes in the availability of one particular metabolite – acetyl-CoA – has dramatic effects on one type of epigenetic modification known as histone acetylation.  Preliminary findings indicate that Kras mutations within the mouse pancreas lead to altered levels of histone acetylation, and that signaling pathways activated by Kras control acetyl-CoA production. Thus, Kras might cause pancreatic cancer in part through its effects on metabolism and epigenetics.  The objective of our work is to investigate the mechanisms linking Kras activation to the regulation of histone acetylation and to functionally test the importance of Kras-driven acetyl-CoA production and histone acetylation on gene expression, tumor development, and tumor growth.  Results of this study could pave the way towards innovative new strategies to target pancreatic cancer, exploiting the interface between metabolism and epigenetics.

Top of Page

2013 Grantees

Eric R. Lutz, PhDEric R. Lutz, PhD
Assistant Professor, Johns Hopkins University, Baltimore, MD

Exploiting the Cancer Mutome for Personalized Tumor Immunotherapy 

Pancreatic cancer is the fourth leading cause of cancer-related deaths due to the lack of adequate interventions for treatment and prevention, and screening methods. Because pancreatic cancer is naturally resistant to current chemotherapy and radiation approaches, new therapeutic strategies that specifically target cancer-specific pathways are required for the successful treatment and prevention of this disease. Vaccine-based immunotherapy is one form of targeted therapy that has the ability to target proteins involved in pancreatic cancer initiation, progression, and metastases, some of which include mutated oncogenes (such as KRAS) and tumor suppressor genes (such as p53). 

"The goal for pancreatic cancer vaccines is to train the immune system to see pancreatic cancer cells as foreign, ultimately resulting in their destruction. Accomplishing this goal depends on activating immune effector T cells capable of specifically recognizing and killing tumor cells. A major obstacle has been identifying targetable T-cell antigens expressed by pancreatic cancer cells, but not normal cells. This is important not only for minimizing the risk of inducing autoimmunity, but also because natural immune tolerance mechanisms exist for depleting and inhibiting T cells that recognize antigens expressed by normal tissues. Recent advances in DNA sequencing technologies have provided the opportunity to perform large-scale genomic analysis of large numbers of human pancreatic cancers. These sequence analyses have shown that pancreatic cancer cells possess an average of 63 non-synonomous somatic mutations (called the “mutome”). Since these mutations occur during tumor development, and are not encountered by the patient prior to the onset of tumorigenesis, each mutation generates a novel and essentially foreign antigen. Although some mutations in pancreatic cancers are in common genes and cellular pathways, the majority are unique and not shared between patients’ tumors. Because these mutant antigens are not only unique to the tumor, but also to each patient, we propose that vaccines targeting them provide a new and innovative approach for personalized pancreatic cancer-specific immunotherapy."

"The Pancreatic Cancer Action Network-AACR Career Development Award will allow us to develop the rationale and methods required for testing this approach in patients with pancreatic cancer. For this approach to work, we must establish methods for comprehensively identifying each patient’s tumor-specific mutations; show that tumor mutations generate antigens capable of being recognized by patient T cells; develop vaccination strategies for stimulating mutation-specific T cells and inducing potent antitumor responses; and develop strategies for measuring vaccine activity. Strategies for identifying tumor mutations directly from tumor tissue are already established. However, since it will be important to target at least one mutation expressed by every tumor cell, in this study, we will investigate whether the analysis of one small piece of tumor results in the identification of mutations present in the total population of cancer cells within a tumor. Recent work from our group and others suggest that a substantial fraction of tumor mutations generate immunogenic antigens capable of being recognized by T cells. Furthermore, in mice, activation of tumor mutation-specific T cells by immunizing with mutation-spanning synthetic peptides has been shown to result in protective antitumor responses. In this study, we will use two mouse pancreatic cancer models to optimize vaccination strategies for inducing tumor mutation-specific T cells and antitumor responses. Finally, we will establish strategies for measuring vaccine activity by analyzing the induction of tumor mutation-specific T cell responses in patients treated with a whole-cell pancreatic cancer vaccine also being developed by our group. If successful, we expect to employ the strategies developed by this study in the first clinical trial testing personalized immunotherapy in patients with pancreatic cancer."

Top of Page

Andrew D. Rhim, MDAndrew D. Rhim, MD
Assistant Professor of Medicine at the University of Michigan Medical School, Ann Arbor, MI

Using Human Circulating Pancreas Cells as a Biomarker for Early PDAC 

At the time of diagnosis, more than 80 percent of patients with PDAC have late-stage disease, when tumor cells have already metastasized and are refractory to therapy. One strategy to improve survival in patients with PDAC is to diagnose this cancer at early stages, prior to metastasis, when current treatments are most efficacious. 

"Our recent studies suggest a novel strategy to identify patients with the earliest forms of cancer. We discovered a new type of cell that arises when precancerous lesions that are destined to form tumors are found in the pancreas: the circulating pancreatic cell (CPC). CPCs are unique pancreas-derived cells found in the blood circulation. We found CPCs in genetically engineered mice with precancerous lesions of the pancreas destined to turn into cancer, before overt tumors formed (Rhim et al, Cell 2012). Furthermore, using a sensitive microfluidic device, we detected CPCs in a portion of patients with precancerous cystic lesions of the pancreas, up to a third of whom will develop PDAC (CPCs were found in 0 percent of controls and 88 percent of PDAC patients). Thus, CPCs can be found in patients who may harbor early, undetectable PDAC."

"The PanCAN Career Development Award will allow me to assess if CPC analysis can predict which patients at high-risk for PDAC (patients with strong family history and those with precancerous lesions of the pancreas) will develop cancer. We will perform a novel prospective clinical study to enumerate, isolate and characterize CPCs from patients and attempt to correlate our findings to the development of cancer. In this way, we hope to learn more about the earliest steps of tumor formation and metastasis and determine if CPC analysis may have utility in stratifying PDAC risk in our patients."

Top of Page

Pankaj Kumar Singh, PhDPankaj Kumar Singh, PhD
Assistant Professor, University of Nebraska, University of Nebraska Medical Center, Omaha, NE

Targeting a Novel Metabolic Chemoresistance Mechanism in Pancreatic Cancer 

"Pancreatic cancer is the fourth leading cause of cancer-related deaths with a five-year survival rate of 6 percent. The poor prognosis of this malignancy also reflects resistance to the current standard of care (gemcitabine). The resistance to gemcitabine is mostly due to intrinsic factors or the stromal (non-tumor cell component of the tumor) environment that limits the accessibility of the tumor cells to the drug. By utilizing our unique cell-based models, animal models and unique techniques, we will delineate and target the mechanism of gemcitabine resistance in pancreatic cancer. Our preliminary data demonstrate a novel metabolic mechanism of gemcitabine resistance in pancreatic cancer. We demonstrate that the glucose flux through pyrimidine biosynthetic pathway is enhanced in our gemcitabine-resistant models. Although over five hundred-fold more resistant to gemcitabine, these cells are less viable under low glucose conditions, in comparison to the control cells. Furthermore, increased expression of enzymes in pyrimidine biosynthetic pathway correlates with poor prognosis of pancreatic cancer patients on pyrimidine analog therapies (gemcitabine and 5-FU)."

"Research supported by the Pancreatic Cancer Action Network-AACR Career Development Award will investigate, for the first time, the efficacy of targeting pyrimidine biosynthetic pathway in improving gemcitabine response. We will also determine if modulating metabolism in tumor cells can alter their surrounding environment to make the tumor cells more accessible and responsive to the chemotherapy. Thus, the resulting information is likely to generate novel diagnostic and therapeutic targets, and biomarkers for managing chemotherapy resistance that is associated with significant mortality in pancreatic cancer."

Top of Page

Daolin Tang, MD, PhDDaolin Tang, M.D., PhD
Assistant Professor, Department of Surgery, University of Pittsburgh, Pittsburgh, PA

Role of HMGB1 in Pancreatic Cancer Initiation and Progression 

"Why is pancreatic cancer so aggressive and deadly? What controls early events in pancreatic tumorigenesis? The Pancreatic Cancer Action Network-AACR Career Development Award will allow us to answer these questions by using a novel genetically modified mouse model of pancreatic cancer that was recently developed in my lab. This award will hopefully provide me the necessary preliminary data to develop a competitive NIH R01 grant application."

"High mobility group box 1 protein (HMGB1), a chromatin-associated nuclear protein and extracellular damage associated molecular pattern molecule (DAMP), is an evolutionarily ancient and critical regulator of cell death and survival. To examine the role of HMGB1 in pancreatic carcinogenesis, we generated mice with pancreas-specific disruption of HMGB1 in the presence of oncogenic K-Ras. To our knowledge, this genetically engineered mouse model develops pancreatic intraepithelial neoplasia the fastest of any vertebrate. Our central hypothesis is that intracellular HMGB1 functions as a previously unrecognized tumor suppressor gene and is a key regulator of pancreatic cancer initiation and progression. This research aims to elucidate how intracellular HMGB1 acts in pancreatic tumorigenesis, with the ultimate goal of devising better prevention and treatment strategies for pancreatic cancer."

Top of Page

Pancreatic Cancer Action Network – AACR Career Development Award, in memory of Skip Viragh

Monte M. Winslow, PhDMonte M. Winslow, PhD
Assistant Professor, Department of Genetics, Stanford University, Stanford, CA

Molecular Dissection of Hmga2 Function during Pancreatic Cancer Progression 

“Pancreatic ductal adenocarcinoma (PDAC) is a prevalent and almost uniformly fatal cancer. Several factors contribute to the poor outcome of PDAC patients but, as in most solid tumors, the ability of cancer cells to leave the primary tumors and establish inoperable metastases is a major impediment to successful therapy. Many of the mutations that occur in human PDAC have been identified, but the molecular and cellular changes that underlie tumor progression and metastasis remain less well characterized."

“The Pancreatic Cancer Action Network-AACR Career Development Award will support our efforts to better understand PDAC invasion and metastasis. We previously identified the chromatin associate protein, Hmga2 as an important regulator of lung cancer metastasis. Hmga2 is highly expressed during development, absent in most adult tissues, and re-expressed in several human cancers. Based on the hypothesis that metastasis of different cancers might be driven by similar mechanisms, we analyzed several mouse models of PDAC and found a striking correlation between Hmga2 expression and invasive cancer cell cytology. We hypothesize that Hmga2 is a key regulator of PDAC invasion and metastatic progression. We will use a genetically engineered mouse model to quantitatively assess the role of Hmga2 on PDAC progression in vivo. Unbiased characterization of PDAC cells with altered Hmga2 expression will also uncover the Hmga2-regulated genes and pathways that drive the malignant features of advanced PDAC. We anticipate that this study will be the beginning of our efforts to systemically understand the functional networks that make PDAC so aggressive."

“Our study will advance our understanding of PDAC and provide insight into common mechanisms the drive tumor progression and metastasis. This may allow the clinical development of therapies to inhibit PDAC invasion or uncover vulnerabilities that could be exploited to irradiate PDAC metastases and significantly improve pancreatic cancer patient outcome.”

Top of Page

2012 Grantees

Pancreatic Cancer Action Network-AACR Career Development Award, supported by The Daniel and Janet Mordecai Foundation

Jiyoung Ahn, PhD, Pancreatic Cancer Action Network-AACR Career Development Award 2012 GranteeJiyoung Ahn, PhD
Assistant Professor, New York University School of Medicine, New York, NY
Oral Microbiome and Pancreatic Cancer: A Prospective Case-Control Study


"Pancreatic cancer is highly fatal; almost all patients (95 percent) die within five years of diagnosis. Currently, there is no effective way to tell who will develop pancreatic cancer and how it can be prevented. Our hypothesis is that certain types of oral bacteria potentiate pancreatic cancer by causing inflammation in the pancreas. I will test our hypothesis in a large population-based prospective study of about 70,000 subjects from whom we have collected oral samples and comprehensive demographic and lifestyle information and who we have been followed for pancreatic cancer development for up to 10-years. I will measure about 300 species of oral bacteria, using a novel bacteria DNA sequencing method, from 150 study participants who subsequently developed pancreatic cancer and 150 participants who did not develop pancreatic cancer. Pancreatic Cancer Action Network-AACR grant will provide an excellent opportunity to identify specific oral bacteria associated with the development of pancreatic cancer. This study is important because identifying these bacteria may improve our limited knowledge about how pancreatic cancer develops, may provide a novel way to identify people at high risk of developing pancreatic cancer, and may help us to develop ways to prevent pancreatic cancer by administering specific drugs or probiotics to modify these oral bacteria."

Top of Page

Pancreatic Cancer Action Network-AACR Career Development Award, supported by The Daniel and Janet Mordecai Foundation

Darren R. Carpizo, MD, PhD, Pancreatic Cancer Action Network-AACR Career Development Award 2012 GranteeDarren R. Carpizo, MD, PhD

Resident Member, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Pre-Clinical Studies of an Allele-Specific p53 Mutant Reactivating Compound in Pancreatic Cancer 

"I am a surgical oncologist who specializes in the management of pancreas cancer patients, as well as a cancer researcher in the field of developmental therapeutics. One of the biggest problems that we face as pancreatic cancer surgeons is that of recurrence. Recurrence cannot be mitigated with more effective surgery but rather more effective chemotherapy. Our laboratory is interested in studying compounds that target mutant p53. The next generation of anti-cancer drugs is defined by compounds that selectively kill cancer cells while leaving normal cells undisturbed. We have identified such a compound that selectively kills cells with a p53-R175 mutation while leaving normal cells undisturbed. This compound restores the wildtype structure and function to one of the most common p53 mis-sense mutants. The potential pool of patients for this drug in the United States annually is approximately 32,000. This work has been accepted for publication in the journal Cancer Cell. My research mentor is Dr. Arnold Levine, whose laboratory discovered the p53 tumor suppressor."

"The project that will be funded by this award is to conduct pre-clinical studies of this mutant p53 reactivating compound in a transgenic mouse model of pancreatic cancer. TP53 is second only to Kras as the most commonly mutated gene in pancreatic cancer. More specifically we will learn the pharmacokinetics and pharmacodynamics of the drug that will allow us to determine if the drug has efficacy in pancreatic cancer mice driven by mutant Kras and p53 alleles. We will also determine if the drug can enhance the efficacy of cytotoxic chemotherapy as well as radiation. My co-mentor for these studies will be Dr. Joseph Bertino, an internationally recognized expert in developmental therapeutics."

"I would like to thank the AACR and the Pancreatic Cancer Action Network for giving me this Career Development Award. In addition, I would like to thank Dr. Arnold Levine for his support and mentorship as well as that of the Cancer Institute of New Jersey."  

Top of Page

Pancreatic Cancer Action Network-AACR Career Development Award, supported by The Daniel and Janet Mordecai Foundation

Kazuki N. Sugahara, MD, Ph.D., Pancreatic Cancer Action Network-AACR Career Development Award 2012 GranteeKazuki N. Sugahara, MD, PhD
Postdoctoral Residency Fellow and Adjunct Associate Research Scientist in the Department of Surgery, Columbia University, New York, NY

Tissue-Penetrating Drug Delivery to Desmoplastic Pancreatic Tumors

Pancreatic cancer is one of the most challenging targets for anti-cancer agents. Pancreatic tumors are packed with fibrotic stroma that inhibits drug distribution within the tissue. The poor drug penetration leads to failure of initial therapy, and eventually, to drug resistance. We have recently identified a peptide that delivers drugs deep into solid tumors and enhances drug efficacy. The peptide, iRGD, belongs to a novel group of peptides (CendR peptides) that interact with a tissue penetration receptor, neuropilin-1 (NRP-1). Most importantly, iRGD facilitates tumor-specific tissue penetration of co-administered free drugs, as well as drugs chemically tethered to the peptide. Thus theoretically, any drug, right from the physician’s cabinet, can be easily potentiated by iRGD. Our recent data indicate that iRGD is particularly efficient in penetrating pancreatic tumors demonstrating its potential in becoming a powerful arsenal of pancreatic cancer treatment.

"PanCAN and AACR have committed a major support to our project in translating the iRGD technology to the clinic. In this project, we will examine the utility of iRGD in targeting human pancreatic cancer, and establish a method to stratify patients to iRGD therapy. First, we will test the efficacy of iRGD-drug combinations in the KPC mouse model, one of the most clinically relevant pancreatic cancer models currently available. Second, we will create a panel of patient-derived pancreatic cancer mouse models with various NRP-1 expression patterns, and validate the iRGD therapies in the mice. These studies will help us estimate the efficacy of iRGD therapies in human patients, and define the patient population that responds to the therapies based on NRP-1expression. With support from PanCAN and AACR, we hope to provide a firm basis for clinical translation of iRGD, and guide future clinical trials to success."

Top of Page